CONTIPRO AS

Their core work

Contipro is a Czech biotech SME specializing in hyaluronic acid-based biomaterials and advanced drug delivery systems. They develop formulations — particles, hydrogel matrices, and scaffolds — designed for therapeutic applications including nose-to-brain delivery and implantable devices. Their core industrial capability spans GMP manufacturing, galenic development, and scale-up of biopharmaceutical products, making them a production-ready partner rather than a purely research-focused lab.

What they specialise in

How they've shifted over time

Contipro's early H2020 work (2015–2018) centered on manufacturing and formulation challenges — GMP production, scale-up, galenic development of multifunctional particles and hydrogel matrices using hyaluronic acid and chitosan. Their later projects (2019–2024) shifted toward specific therapeutic applications, particularly multiple sclerosis treatment and CNS drug delivery using biomaterial scaffolds and intranasal biopharmaceutics. The trajectory shows a company moving from process-focused manufacturing partner toward a more application-specific role in neurological disease therapies.

Contipro is deepening its specialization in nose-to-brain delivery of biologics for neurological conditions — a strong signal for anyone building consortia targeting CNS therapeutics or advanced biopharmaceutical delivery.

How they like to work

Contipro participates exclusively as a partner, never as coordinator — typical for a specialized SME that contributes specific industrial capabilities to larger research consortia. With 34 unique partners across 11 countries in just 4 projects, they operate in broad European consortia and appear comfortable integrating into large, multinational teams. Their consistent role suggests they are sought after as a reliable manufacturing and formulation partner rather than as a project initiator.

Contipro has built a network of 34 consortium partners across 11 countries through just 4 projects, indicating participation in large, well-connected consortia. Their collaborative reach spans much of the EU, with no apparent geographic limitation.

What sets them apart

Contipro bridges the gap between academic biomaterial research and industrial production — they bring GMP manufacturing, PAT, and scale-up expertise that most university partners cannot offer. Their deep specialization in hyaluronic acid formulations gives them a distinctive material platform few SMEs in Central Europe can match. For consortium builders, they solve the common problem of "who will actually manufacture this at scale" in biomedical projects.

Highlights from their portfolio

• DRIVE
  Largest single EC contribution (EUR 600,625) and their earliest H2020 project, focused on diabetes-reversing implants — showing Contipro's entry into medical device manufacturing.
• N2B-patch
  Most keyword-rich project revealing Contipro's core competencies: hyaluronic acid, chitosan, GMP, PAT, scale-up — the full chain from formulation to manufacturing.
• Bio2Brain
  Their most recent project (2021–2024), continuing the nose-to-brain delivery line with biopharmaceutics — confirms this as their strategic direction.